Cosmo Pharmaceuticals N.V.

28.04.2021 – 14:01
Invitation to Cosmo's GI Genius(TM) Q&A session for investors, analysts and journalist
Dublin (ots/PRNewswire) - Cosmo Pharmaceuticals N.V. (SIX: COPN) ( XETRA: C43) invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4th of May 2021 to discuss GI Genius(TM), the first device approved by the US Food and Drug Administration[1] (FDA) that uses artificial intelligence to help detect potential ...
mehr
12.04.2021 – 07:00
Cosmo announces FDA approval of GI Genius(TM) intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy
Dublin (ots/PRNewswire) - Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius(TM) intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy. The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research ...
mehr